MA49253A - Compositions solides pour administration orale - Google Patents

Compositions solides pour administration orale

Info

Publication number
MA49253A
MA49253A MA049253A MA49253A MA49253A MA 49253 A MA49253 A MA 49253A MA 049253 A MA049253 A MA 049253A MA 49253 A MA49253 A MA 49253A MA 49253 A MA49253 A MA 49253A
Authority
MA
Morocco
Prior art keywords
oral administration
solid compositions
compositions
solid
oral
Prior art date
Application number
MA049253A
Other languages
English (en)
Inventor
Simon Bjerregaard
Susanne Schéele
Andreas Vegge
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59070439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49253(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA49253A publication Critical patent/MA49253A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA049253A 2017-06-09 2018-06-11 Compositions solides pour administration orale MA49253A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17175131 2017-06-09

Publications (1)

Publication Number Publication Date
MA49253A true MA49253A (fr) 2020-04-15

Family

ID=59070439

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049253A MA49253A (fr) 2017-06-09 2018-06-11 Compositions solides pour administration orale

Country Status (28)

Country Link
US (2) US11167014B2 (fr)
EP (1) EP3634468B1 (fr)
JP (1) JP7239495B2 (fr)
KR (1) KR20200015564A (fr)
CN (1) CN110769846A (fr)
AR (1) AR112015A1 (fr)
AU (1) AU2018280875A1 (fr)
BR (1) BR112019025769A2 (fr)
CA (1) CA3064677A1 (fr)
CL (1) CL2019003402A1 (fr)
CO (1) CO2019013047A2 (fr)
DK (1) DK3634468T5 (fr)
ES (1) ES2938050T3 (fr)
FI (1) FI3634468T3 (fr)
HR (1) HRP20230075T1 (fr)
HU (1) HUE060962T2 (fr)
IL (1) IL270812B2 (fr)
MA (1) MA49253A (fr)
MX (1) MX2019013965A (fr)
MY (1) MY197488A (fr)
PE (1) PE20200606A1 (fr)
PH (1) PH12019550249A1 (fr)
PL (1) PL3634468T3 (fr)
PT (1) PT3634468T (fr)
RS (1) RS64045B1 (fr)
SI (1) SI3634468T1 (fr)
TW (1) TWI797133B (fr)
WO (1) WO2018224689A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020130502A1 (fr) * 2018-12-21 2020-06-25 (주)휴온스 Composition pharmaceutique comprenant l'empagliflozine et la sitagliptine
PH12022550007A1 (en) * 2019-08-07 2022-11-21 Novo Nordisk As Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2021089752A1 (fr) * 2019-11-07 2021-05-14 Novo Nordisk A/S Compositions solides comprenant un agoniste de glp-1, un inhibiteur de sglt2 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino) caprylique
CN115461044B (zh) * 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
WO2023065231A1 (fr) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Administration orale d'agents thérapeutiques
CN118742326A (zh) * 2021-12-29 2024-10-01 广州大洲生物医药科技有限公司 口服递送
EP4299052A1 (fr) * 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un agent améliorant la perméation
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
JP2026509773A (ja) * 2023-03-06 2026-03-25 アセンディス ファーマ エー／エス アルブミン結合性部分を含む薬物化合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2001092206A1 (fr) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Procede de preparation de salicylamides
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AR059489A1 (es) 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
WO2007121318A2 (fr) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Préparations destinées à l'administration d'insuline
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
US20080287529A1 (en) 2007-05-18 2008-11-20 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
EP2190872B1 (fr) 2007-09-05 2018-03-14 Novo Nordisk A/S Dérivés de glucagon-like peptide-1 et leur utilisation pharmaceutique
JP2012528170A (ja) 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
EP2498759B1 (fr) 2009-11-13 2018-08-01 AstraZeneca AB Formulations pour comprimés à libération immédiate
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
US20130224300A1 (en) 2011-08-26 2013-08-29 Edward T. Maggio Compositions and methods thereof for oral administration of drugs
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
JP6517690B2 (ja) * 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
CN105188736A (zh) 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
ES2741507T3 (es) 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
CA2993215C (fr) * 2015-07-02 2023-10-31 Rani Therapeutics, Llc Preparations d'agent therapeutique a administrer dans une lumiere du tractus intestinal au moyen d'un dispositif d'administration de medicament avalable
WO2018096164A1 (fr) 2016-11-28 2018-05-31 Novo Nordisk A/S Insuline dégludec pour le traitement du diabète
JP2019535791A (ja) 2016-11-28 2019-12-12 ノヴォ ノルディスク アー／エス 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク
US11278596B2 (en) 2016-11-28 2022-03-22 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
PH12022550007A1 (en) * 2019-08-07 2022-11-21 Novo Nordisk As Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Also Published As

Publication number Publication date
PH12019550249A1 (en) 2020-07-13
IL270812B1 (en) 2023-09-01
FI3634468T3 (fi) 2023-02-19
PT3634468T (pt) 2023-03-28
BR112019025769A2 (pt) 2020-06-30
TWI797133B (zh) 2023-04-01
RS64045B1 (sr) 2023-04-28
DK3634468T5 (da) 2024-09-02
ES2938050T3 (es) 2023-04-04
HUE060962T2 (hu) 2023-04-28
AU2018280875A1 (en) 2019-12-12
MX2019013965A (es) 2020-01-23
RU2019139082A3 (fr) 2021-09-16
EP3634468A2 (fr) 2020-04-15
PL3634468T3 (pl) 2023-03-13
SI3634468T1 (sl) 2023-02-28
JP2020522559A (ja) 2020-07-30
CL2019003402A1 (es) 2020-03-20
US20200147179A1 (en) 2020-05-14
CO2019013047A2 (es) 2020-04-01
JP7239495B2 (ja) 2023-03-14
IL270812B2 (en) 2024-01-01
AR112015A1 (es) 2019-09-11
CN110769846A (zh) 2020-02-07
RU2019139082A (ru) 2021-06-02
DK3634468T3 (da) 2023-02-06
WO2018224689A3 (fr) 2019-02-28
PE20200606A1 (es) 2020-03-10
TW201904583A (zh) 2019-02-01
CA3064677A1 (fr) 2018-12-13
IL270812A (en) 2020-01-30
HRP20230075T1 (hr) 2023-03-17
EP3634468B1 (fr) 2022-12-14
US20220016216A1 (en) 2022-01-20
US11167014B2 (en) 2021-11-09
KR20200015564A (ko) 2020-02-12
MY197488A (en) 2023-06-19
WO2018224689A2 (fr) 2018-12-13

Similar Documents

Publication Publication Date Title
MA49253A (fr) Compositions solides pour administration orale
EP3423037A4 (fr) Composition administrable par voie orale
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
EP3368084A4 (fr) Compositions pharmaceutiques pour administration par voie transmuqueuse
DK3529248T3 (da) Farmaceutiske sammensætninger
EP3310439A4 (fr) Compositions pharmaceutiques pour des applications anesthésiologiques
EP3573614C0 (fr) Compositions pharmaceutiques pour thérapie combinée
DK3244878T3 (da) Faste orale sammensætningsformer
FR3027521B1 (fr) Compositions pour administration par voie orale
EP3375432A4 (fr) Composition pour la cavité buccale
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
EP3403644A4 (fr) Préparation pour la cavité orale
EP3565532A4 (fr) Composition de film dispersible oral
EP3756471A4 (fr) Composition d'ingestion orale
EP3914234A4 (fr) Compositions pharmaceutiques
GB201804548D0 (en) Pharmaceutical compositions
DK3706724T3 (da) Orale rifamycin-sv-sammensætninger
EP3318259A4 (fr) Composition pharmaceutique stable pour administration par voie orale
MA49837A (fr) Compositions pharmaceutiques
EP3790543A4 (fr) Compositions et formes posologiques pour administration orale
EP3793609C0 (fr) Formulation de solution orale
GB201808571D0 (en) Pharmaceutical compositions
GB201808567D0 (en) Pharmaceutical compositions
EP3528818A4 (fr) Compositions pharmaceutiques